





RealRate

PHARMACEUTICAL 2020

Sarepta Therapeutics Inc. Rank 210 of 358



The relative strengths and weaknesses of Sarepta Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sarepta Therapeutics Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 24% points. The greatest weakness of Sarepta Therapeutics Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 88% points.

The company's Economic Capital Ratio, given in the ranking table, is 49%, being 13% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	1,468,913
Cost of Goods Sold	0
Intangible Assets	12,497
Liabilities, Current	264,767
Liabilities, Non-Current	57,968
Other Assets	211,792
Other Compr. Net Income	149
Other Expenses	241,870
Other Liabilities	681,900
Other Net Income	-8,317
Other Revenues	380,833
Property and Equipment	129,620
Research and Development	560,909
Selling, General and Administrative Expense	284,812

Output Variable	Value in 1000 USD
Assets	1,822,822
Liabilities	1,004,635
Expenses	1,087,591
Revenues	380,833
Stockholders Equity	818,187
Net Income	-715,075
Comprehensive Net Income	-715,000
Economic Capital Ratio	49%